Germany’s medtech companies have finally achieved a reasonable rise in annual revenues, with averages of 5-7% being recorded by some of the bigger players recently. SMEs are seeing increases of 3-4%.
MDR Is The ‘Mother Of European Industry’s Problems’ − Germany's BVMed At Medica 2023
One in 10 German medtechs will not survive the €7bn+ journey to EU regulatory compliance
Higher logistics and energy costs are putting medtech P&Ls under pressure, and compliance with the EU MDR is draining any remaining surplus. Sustainability compliance is another cost to factor in, says BVMed chief executive Marc-Pierre Möll in part 2 of his interview with Medtech Insight at Medica 2023.
